Amarillo Biosciences, Inc. (ABI) is engaged in developing biologics for the treatment of human and animal diseases. The Company is continuing its clinical studies as part of the process of obtaining regulatory approval from the United States Food and Drug Administration (FDA), so that commercial marketing can begin in the United States. ABI is focusing its research on human health indications for the use of low-dose, orally administered natural human interferon alpha, particularly for the treatment of Sjogren's syndrome, Behcet's disease, fibromyalgia, idiopathic pulmonary fibrosis and oral warts in human immunodeficiency virus (HIV) patients. The Company owns or licenses 16 United States patents relating to the use or composition of low-dose, oral, natural interferon alpha. ABI has filed five investigational new drug (IND) applications with the FDA, covering indicated uses for low-dose, oral interferon alpha, including treatment of Sjogren's syndrome, oral warts and fibromyalgia.